Vine Brook Capital

1606 Words Mar 27th, 2013 7 Pages
To: Hardina Smythe
From: FT35312
Subject: Vine Brook Capital
Date: November 17th 2012

Summary:
Vine Brooks Capital closed in April 2009 with $350 Million of investor commitments and though the last decade had been one filled with highs and lows, the firm realizes that they need to play a bigger game in health care market. However firms were generally taking a longer and more cautious approach with the idea that they want to provide more than just initial seed funding but also provide enough to get the product from the earliest stages to the market. (Rhodes-Kroff, leamon, Strope, 2011)

The Investment Choices:

(1) Always Covered Software: A software system for hospitals to manage an auction based registry
…show more content…
Both XD10 and the competition were not completely void of side effects. There were similar other new drugs in development. Points of Difference: XD10 lasted longer, potentially worked better and had lesser side effects. It already had the backing and financial commitments from the company’s original backers for the phase 3 trials.

Testing Plan: Testing in the market would obviously only be possibly once the phase 3
Trials are complete and approved by the FDA. To make this possible, steps must be taken to have the phase 3 trials completed in the US and approval obtained by the FDA. Market research could then be conducted comparing the effects of the drug compared to other drugs on the market.

Customer Segments and Testing: The market could be divided into segments based on the level of systems of stages of MS. People at different levels would be tested with the approved drug to measure its effectiveness. Based on the success of XD10, the company could then also look into diversifying and developing drugs for diseases that share symptoms with MS

(3) SweetDreams Technology (SDT): An implantable device to reduce effects of Sleep Apnea

Key Features, Pros and Cons: One of the major advantages for SDT is that the only other competitive device and therapy in the market had a 50% drop out rate. Sleep apnea as a condition was only diagnosed

More about Vine Brook Capital